首页> 美国卫生研究院文献>Therapeutic Advances in Medical Oncology >Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis

【2h】

Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis

机译：基于先进驾驶员 - 基因野生型非小细胞肺癌患者的特异性病理特征的优化第一线免疫疗法选择：系统综述和网络荟萃分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Therapeutic Advances in Medical Oncology
作者
Lei Sheng; Jing Gao; Qian Xu; Xue Zhang; Miao Huang; Xin Dai; Song Li; Lian Liu;
展开▼
作者单位

展开▼
年(卷),期 2021(-1),-1
年度 2021
页码 -1
总页数 18
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
anti-angiogenesis; chemotherapy; first-line; immunotherapy; network meta-analysis; non-small cell lung cancer;

机译：抗血管生成;化疗;一线;免疫疗法;网络荟萃分析;非小细胞肺癌;

相似文献

外文文献
中文文献
专利

1. First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis [J] . Tingting Liu, Silu Ding, Jun Dang, Journal of Thoracic Disease . 2019,第7期

机译：具有野生型表皮生长因子受体（EGFR）或间变性淋巴瘤激酶（ALK）的晚期非小细胞肺癌的一线免疫检查点抑制剂：系统评价和网络荟萃分析
2. Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis [J] . Alfredo Addeo, Giuseppe Luigi Banna, Giulio Metro, Frontiers in Oncology . 2019,第4期

机译：化学疗法与免疫检查点抑制剂组合用于先进的非小细胞肺癌患者的一线治疗：系统审查和基于文献的荟萃分析
3. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis [J] . Urania Dafhi Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2019,第1期

机译：免疫检查点抑制剂，单独或与化疗组合，作为先进的非小细胞肺癌的一线治疗。系统审查和网络元分析
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis [O] . Tingting Liu, Silu Ding, Jun Dang, 2019

机译：具有野生型表皮生长因子受体（EGFR）或间变性淋巴瘤激酶（ALK）的晚期非小细胞肺癌的一线免疫检查点抑制剂：系统评价和网络荟萃分析
7. Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis [O] . Jie Liu, Chengming Li, Samuel Seery, 2020

机译：根据PD-L1表达识别高级非小细胞肺癌的最佳第一线干预：系统审查和网络元分析

Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis

著录项

相似文献

相关主题

期刊订阅